PHS.F PHOTOCURE ASA NK-50

Healthcare Pharmaceuticals Frankfurt Exchange
3.84 EUR
Close of Nov 12, 2026
3.84 6.71
Market cap
EUR 104M
P/E
24.0x
P/B
1.89x
ROE
12.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PHS.F undervalued?

Graham number
Price3.84
Graham value2.71
Premium41.8%

PHS.F trades 41.8% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

PHOTOCURE ASA NK-50 fundamental analysis

No fundamental analysis for PHOTOCURE ASA NK-50 yet.

PHOTOCURE ASA NK-50 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About PHOTOCURE ASA NK-50

Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through two segments, Commercial Franchise and Development Portfolio. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It is also developing Cevira, a photodynamic drug-device combination product candidate for the non-surgical treatment of high-grade cervical dysplasia. …

Full company profile